021-51111890
购物车（0）
sales@molnova.cn
SBI-115
CAS No. 882366-16-7
SBI-115 ( —— )
产品货号. M20784 CAS No. 882366-16-7
SBI-115 是 TGR5 的拮抗剂。 SBI-115 通过抑制 TGR5 减少多囊肝病的肝囊肿发生。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥389 | 有现货 |
|
| 10MG | ￥599 | 有现货 |
|
| 25MG | ￥1199 | 有现货 |
|
| 50MG | ￥1879 | 有现货 |
|
| 100MG | ￥3029 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称SBI-115
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述SBI-115 是 TGR5 的拮抗剂。 SBI-115 通过抑制 TGR5 减少多囊肝病的肝囊肿发生。
-
产品描述SBI-115 is an?antagonist of?TGR5.?SBI-115 decreases hepatic cystogenesis with polycystic liver diseases via inhibiting TGR5.
-
体外实验SBI-115 (100-200 μM, 24 hours) inhibits proliferation triggered by pre-treatment of cystic cholangiocytes with Taurolithocholic acid (TLCA) in shRNA-transfected ADPKD cholangiocytes. Cell Proliferation Assay Cell Line:shRNA-transfected ADPKD cholangiocytes Concentration:100, 200 μM Incubation Time:24 hours Result:Inhibited proliferation (by 32-48%) triggered by pre-treatment of cystic cholangiocytes with TLCA.
-
体内实验——
-
同义词——
-
通路GPCR/G Protein
-
靶点GPCR19
-
受体TGR5
-
研究领域——
-
适应症——
化学信息
-
CAS Number882366-16-7
-
分子量340.78
-
分子式C14H13ClN2O4S
-
纯度>98% (HPLC)
-
溶解度DMSO:150 mg/mL (440.17 mM)
-
SMILESCCS(=O)(=O)c1ncc(Cl)c(C(=O)Oc2cccc(C)c2)n1
-
化学全称4-Pyrimidinecarboxylic acid 5-chloro-2-(ethylsulfonyl)- 3-methylphenyl ester
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Masyuk TV Masyuk AI Lorenzo Pisarello Met al.TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate/Gαs signaling[J].Hepatology. 2017 Oct;66(4):1197-1218.
产品手册
